Microbiome-Metabolic-Inflammation Triad in AD: Experimental Protocol

Executive Summary

This protocol describes a randomized, placebo-controlled clinical trial to test the Microbiome-Metabolic-Inflammation Triad hypothesis in Alzheimer’s disease (AD)kowalski2019 2019, Gut-brain axis in Alzheimervancassel2021 2021, Targeting the gut-brain axis: therapeutic strategies for Alzheimer. The hypothesis proposes that combined gut microbiome dysbiosis, metabolic dysfunction, and chronic neuroinflammation interact synergistically to drive AD progression^{1Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range.2020 · Diabetes care · DOI 10.2337/dci19-0028 · PMID 31177185Open reference}catana2022 2022, Gut microbiota alterations in Alzheimervogt2018 2018, Gut microbiome alterations in Alzheimer, and that a combined intervention targeting all three pathways will demonstrate superior efficacy compared to single-target approachespistollato2020 2020, Role of gut microbiota and nutrients in amyloid formation and neurotransmission.

Hypothesis

Primary Hypothesis: Combined intervention with GLP-1 agonist (liraglutide) plus multi-strain probiotic will show greater efficacy in improving cerebrospinal fluid (CSF) Alzheimer’s biomarkers and cognitive outcomes compared to placebo in AD patients with metabolic syndrome^{2Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors.2021 · mAbs · DOI 10.1080/19420862.2020.1850395 · PMID 33459147Open reference}MISSING:bassil2020gallagher2019 2019, Liraglutide crosses the blood-brain barrier in humans.

Mechanistic Hypothesis: The triad of microbiome dysbiosis, metabolic dysfunction, and neuroinflammation operates through interconnected pathwayschen2023 2023, Short-chain fatty acids and brain function in Alzheimerschroeder2020 2020, The gut-brain axis and Alzheimer where:

• Gut dysbiosis reduces short-chain fatty acid (SCFA) production, impairing gut-brain axis signaling^{3AGO2 Protects Against Diabetic Cardiomyopathy by Activating Mitochondrial Gene Translation.2024 · Circulation · DOI 10.1161/CIRCULATIONAHA.123.065546 · PMID 38126189Open reference}bonfili2020 2020, Probiotic metabolism and neuroinflammation in Alzheimermulak2021 2021, Bile acids in the gut-brain axis

• Metabolic dysfunction (insulin resistance) disrupts neuronal energy metabolism and promotes inflammationagorastos2021 2021, Metabolic syndrome and Alzheimerli2019 2019, Apolipoprotein E and metabolic syndrome in Alzheimerforouhi2009 2009, Epidemiology of diabetes

• Chronic inflammation accelerates amyloid aggregation and tau phosphorylationbassi2020 2020, GLP-1 receptor agonists and neuroinflammation in Alzheimer

• Combined intervention addresses all three arms simultaneously, enabling synergistic effects

Study Design

Overview

flowchart TD
    MMSE["MMSE"] -->|"regulates"| DIABETES["DIABETES"]
    MMSE["MMSE"] -->|"associated with"| TH["TH"]
    MMSE["MMSE"] -->|"associated with"| APP["APP"]
    MMSE["MMSE"] -->|"associated with"| CLU["CLU"]
    MMSE["MMSE"] -->|"associated with"| CR1["CR1"]
    MMSE["MMSE"] -->|"associated with"| ROS["ROS"]
    MMSE["MMSE"] -->|"associated with"| CSF["CSF"]
    MMSE["MMSE"] -->|"associated with"| IL6["IL6"]
    MMSE["MMSE"] -->|"associated with"| TAU["TAU"]
    TAU["TAU"] -->|"stabilizes"| MMSE["MMSE"]
    DASATINIB["DASATINIB"] -->|"associated with"| MMSE["MMSE"]
    ENTORHINAL_CORTEX["ENTORHINAL CORTEX"] -->|"associated with"| MMSE["MMSE"]
    CORTEX["CORTEX"] -->|"associated with"| MMSE["MMSE"]
    ASTROCYTE["ASTROCYTE"] -->|"associated with"| MMSE["MMSE"]
    style MMSE fill:#4fc3f7,stroke:#333,color:#000

• Design: Randomized, double-blind, placebo-controlled clinical trial

• Duration: 24 weeks (6 months)

• Setting: Multi-center academic medical centers with AD research programs

Participant Flow

Inclusion Criteria

Exclusion Criteria

Intervention Arms

Treatment Arm: GLP-1 Agonist + Probiotic

Component 1: GLP-1 Agonist (Liraglutide)

• Dose: 1.8 mg daily (subcutaneous)

• Titration: Start at 0.6 mg, increase by 0.6 mg weekly

• Rationale: GLP-1 receptors expressed in brain; liraglutide crosses BBBgallagher2019 2019, Liraglutide crosses the blood-brain barrier in humans; improves insulin sensitivity, reduces neuroinflammationbassi2020 2020, GLP-1 receptor agonists and neuroinflammation in Alzheimerbloom2021 2021, Liraglutide effects on brain function in Alzheimer

Component 2: Multi-Strain Probiotic

• Strains: Bifidobacterium longum BB536, Lactobacillus acidophilus NCFM, Bifidobacterium bifidum Bb-02, Lactobacillus rhamnosus HN001

• Dose: 2×10¹⁰ CFU daily

• Delivery: Sachets for oral administration

• Rationale: Selected for SCFA production capacity, anti-inflammatory properties, and prior safety data in elderly populationsmullins2019 2019, Effects of probiotic supplementation on cognitive function in Alzheimersohail2022 2022, Multi-strain probiotics modulate gut microbiome and cognitive functionsandhu2021 2021, Beta-glucan from barley improves gut permeability in Alzheimer

Control Arm: Placebo

• Identical probiotic placebo (maltodextrin)

• Double-dummy design to maintain blinding

Multi-Omics Profiling

1. Gut Microbiome Profiling

Method: Shotgun metagenomic sequencing

Timepoints: Baseline, Week 12, Week 24

Key Outcomes:

• Alpha diversity (Shannon, Simpson)

• Beta diversity (Bray-Curtis, UniFrac)

• SCFA-producing bacteria abundance (Roseburia, Faecalibacterium, Anaerostipes)

• Pathogenic bacteria reduction (Escherichia, Klebsiella)

2. Plasma Metabolomics

Method: LC-MS/MS untargeted metabolomics

Timepoints: Baseline, Week 12, Week 24

Target Analytes:

• SCFAs: acetate, propionate, butyrate, isobutyrate, valerate

• Primary bile acids: cholic acid, chenodeoxycholic acid

• Secondary bile acids: deoxycholic acid, lithocholic acid

• Tryptophan metabolites: kynurenine, 5-HT

3. CSF Inflammatory Cytokines

Method: Multiplex immunoassay (Luminex)

Target Cytokines:

• Pro-inflammatory: IL-6, TNF-α, IL-1β, IL-8

• Anti-inflammatory: IL-10, TGF-β

• Chemokines: MCP-1, MIP-1α

Timepoints: Baseline, Week 24

Outcome Measures

Primary Outcomes

Secondary Outcomes

Exploratory Outcomes

• Gut permeability markers (zonulin, FABP2)

• Neurodegeneration markers (NFL, NfL)

• Brain FDG-PET metabolism (subset)

• Gut microbiome-metabolome-brain axis integration

Statistical Analysis Plan

Sample Size Calculation

Assumptions:

• Effect size (Cohen’s d): 0.70 for primary cognitive outcomeitt2010 2010, Intent-to-treat analysis in clinical trials

• Power: 80%

• Alpha: 0.05 (two-sided)

• Dropout rate: 15%

Calculation:

Adjusted for dropout: 90 participants (45 per arm)

Primary Analysis

Intent-to-Treat (ITT) Population: All randomized participantsitt2010 2010, Intent-to-treat analysis in clinical trials

Statistical Methods:

1. Primary: Mixed-effects model for repeated measures (MMRM)

   • Fixed effects: treatment, time, treatment×time interaction

   • Covariates: baseline score, age, sex, APOE4 status

   • Unstructured covariance matrix

2. Sensitivity: Per-protocol analysis (participants with ≥80% adherence)

3. Multiple comparison adjustment: Bonferroni for primary outcomes

Secondary Analyses

1. Responder analysis: Proportion achieving clinically meaningful improvement

2. Biomarker mediation analysis: Structural equation modeling

3. Microbiome-drug interaction: Machine learning classification

4. Pharmacoeconomic analysis: Cost per QALY

Missing Data Handling

• Primary: Multiple imputation (MICE) under MAR assumption

• Sensitivity: Last observation carried forward (LOCF)

Safety Monitoring

Adverse Event Monitoring

Stopping Rules

• 10% severe GI adverse events: Pause enrollment, review

• 2 or more deaths: Data safety monitoring board review

• Significant cognitive decline (>4 points MMSE): Unblind, consider discontinuation

Data Safety Monitoring Board (DSMB)

• Independent committee

• Interim analysis at Week 12

• Pre-specified stopping boundaries (Pocock method)

Timeline

Budget Estimate

Ethical Considerations

Informed Consent

• Comprehensive written consent in accessible language

• Separate consent for biobanking and optional imaging

• Ongoing consent reinforcement at each visit

Risk-Benefit

• Direct benefit: Potential cognitive improvement

• Indirect benefit: Advancing AD therapeutic knowledge

• Risks: Managed through comprehensive monitoring

Data Privacy

• HIPAA-compliant data management

• Limited dataset for collaborators

• Genetic data handling per NIH guidelines

Related Pages

• Gut-Brain Axis in Neurodegeneration

• Metabolic Syndrome and Alzheimer’s Risk

• Neuroinflammation Mechanisms

• GLP-1 Agonists in Neurology

• Microbiome-Based Therapeutics

• Short-Chain Fatty Acids and Brain Function

• APOE and Metabolic Risk

• Clinical Trial Design Standards

See Also

• NeuroWiki Home

• Index Pages